Rating Change
Chardan Capital analysts reiterated a Buy rating on Opus Genetics, Inc. (NASDAQ:IRD) on July 06, 2026.
reiterateNASDAQ:IRD
Chardan Capital Reiterates Buy Rating on Opus Genetics, Inc. (IRD)
Rating Change Chardan Capital analysts reiterated a Buy rating on Opus Genetics, Inc. (NASDAQ:IRD) on July 06, 2026. Market Context Opus Genetics, Inc.
Market Context
Opus Genetics, Inc. operates in the Healthcare sector. The stock currently trades at $4.07 with a market capitalization of $167.9M. The stock has gained 311.1% over the past 52 weeks.
Analyst coverage from Chardan Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Opus Genetics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Opus Genetics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 06, 2026 | BTIG | Buy | N/A |
| Jul 06, 2026 | Chardan Capital | Buy | N/A |
| Jun 18, 2026 | Chardan Capital | Buy | N/A |
| Jun 17, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 16, 2026 | BTIG | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View IRD Stock Page
Frequently Asked Questions
What does a Buy rating mean for IRD?
A Buy rating from Chardan Capital reflects the analyst's outlook on Opus Genetics, Inc. (NASDAQ:IRD). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the IRD forecast page.